APPLIED CLINICAL TRIALS Issue Alert Having trouble viewing this email? Click here
Web Version | View Digital Edition | Subscribe
In Our June Issue:

FEATURED

 The COVID Catalyst
Ann Neuer
Clinical trial stakeholders offer their perspectives on the patient-centric shifts unfolding in the era of COVID-19, as efforts in drug development move away from the traditional site-based model.

Pandemic Challenges for LMICs
Clint D. Hermes
Examining the five critical hurdles faced by clinical teams conducting studies in low- and middle-income countries amid the quarantine and other restrictions.

Oncology Recruitment: Busting Bottlenecks
T.J. Bowen
How the use of integrated data platforms can help find the best-suited patients for oncology clinical trials and reduce the burden on care teams.

Refining Home Visits
Michael Woods
Home visits as part of clinical trial protocols are not a panacea, but in the age of COVID-19, aligning approaches in quality, control, and oversight can help teams get the most out of their inclusion.

NEWS
Washington Report: Jill Wechsler on the importance of using similar protocols and endpoints in vaccine trials for COVID-19.

EU Report: Peter O’Donnell explores the vulnerability of European regulators and reimbursement agencies seeking support on transparency for COVID drugs.

Q&A: Leader of clinical development analytics company shares findings on the impact of COVID-19 from a recent data review of 300,000 trial sites.

CLINICAL TRIAL INSIGHTS
Assessing Intentional Dose Non-Adherence
Ken Getz
AI has improved the feasibility of direct patient observation and presented a unique opportunity to assess the magnitude of intentional dose non-adherence, a major drug development challenge for decades.
FROM THE EDITOR
A Crisis of Health Literacy
Lisa Henderson
Recent public and patient surveys by CISCRP and others in regard to COVID-19 highlight the larger concern around health and/or scientific literacy—or the lack thereof.
CLOSING THOUGHT
R&D Needs ‘Real’ Change
Travis Leonardi, William Kirsh
The only way for pharma companies to know where to focus their COVID-19 R&D efforts is for the industry to have access to real-time, real-world evidence of what’s working to keep people alive.
View the digital Issue
image
 
BLOGS
Clinical Trial Site Training in the Era of COVID
Resurrecting ‘Zombie’ Trials will be Another Consequence Unless the Industry Acts Now
Immuno-oncology Enterprises Entering COVID
WEBCAST
Beyond EDC – Don’t Just Capture Data, Collect It
Learn why a transformative shift in clinical data collection needs to happen now, including leveraging a unified platform to reduce operational inefficiency and streamline workflow.

If you would like to submit an article to Applied Clinical Trials, contact Lisa Henderson, Editorial Director - lhenderson@mjhlifesciences.com

Applied Clinical Trials is free to qualified subscribers. To subscribe, click here.

Click here to contact the Applied Clinical Trials sales team.
Twitter LinkedIn